Table 1.
Baseline characteristics and concomitant medications
| Category | Aripiprazole lauroxil regimen | ||
|---|---|---|---|
| 1064 mg q8wk (n = 35) | 882 mg q6wk (n = 34) | 441 mg q4wk (n = 35) | |
| Age, mean ± SD (years) | 44.9 ± 10.7 | 44.8 ± 12.4 | 46.3 ± 11.0 |
| Men, n (%) | 29 (82.9) | 25 (73.5) | 20 (57.1) |
| Hispanic or Latino, n (%) | 4 (11.4) | 2 (5.9) | 1 (2.9) |
| Race, n (%) | |||
| Black or African American | 26 (74.3) | 25 (73.5) | 26 (74.3) |
| White | 9 (25.7) | 8 (23.5) | 9 (25.7) |
| American Indian or Alaska Native | 0 | 1 (2.9) | 0 |
| Body mass index, mean ± SD (kg/m2) | 29.3 ± 4.4 | 29.3 ± 4.4 | 30.3 ± 4.3 |
| Weight, mean ± SD (kg) | 88.5 ± 18.3 | 88.6 ± 15.9 | 92.5 ± 16.4 |
| CGI-S score, mean ± SD | 2.9 ± 0.43 | 2.8 ± 0.46 | 2.9 ± 0.32 |
| Patients taking concomitant antipsychotic medications, n (%) | 35 (100) | 33 (97.1) | 35 (100) |
| Antipsychotic medications taken by ≥ 10% of patients | |||
| Risperidone, n (%) | 12 (34.3) | 9 (26.5) | 16 (45.7) |
| Dose/day, mean ± SD (mg) | 4.0 ± 1.9 | 3.8 ± 1.5 | 3.4 ± 1.9 |
| Quetiapine, n (%) | 9 (25.7) | 10 (29.4) | 6 (17.1) |
| Dose/day, mean ± SD (mg) | 433.3 ± 173.2 | 430.0 ± 240.6 | 400.0 ± 209.8 |
| Olanzapine, n (%) | 6 (17.1) | 8 (23.5) | 6 (17.1) |
| Dose/day, mean ± SD (mg) | 12.5 ± 6.1 | 15.0 ± 7.6 | 12.5 ± 5.2 |
| Haloperidol, n (%) | 4 (11.4) | 3 (8.8) | 4 (11.4) |
| Dose/day, mean ± SD (mg) | 3.5 ± 1.7 | 7.3 ± 4.6 | 12.8 ± 9.1 |
CGI-S Clinical Global Impression − Severity, q4wk every 4 weeks, q6wk every 6 weeks, q8wk every 8 weeks